PDLIM7 and neoplasm: Infusion of these engineered T cells into immunocompromised mice revealed specific activation by low peptide concentrations and efficient recognition of LMP1-expressing tumour cells, demonstrating high avidity for antigen recognition in EBV-associated malignancies (23).